Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

A drug used by cancer patients may make chemotherapies less effective in patients with obesity — but many doctors are in the ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...